Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 7, 2003, Pages 1566-1574

  Bouma, B N ^a,b   Meijers, J C M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Carboxypeptidase B; Carboxypeptidase U; Fibrinolysis; TAFI

Indexed keywords

LYSINE; PLASMIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOWN REGULATION; FIBRINOLYSIS; HUMAN; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW; TIME;

ANIMALS; CARBOXYPEPTIDASE U; DOWN-REGULATION; FIBRINOLYSIS; HUMANS; LYSINE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PLASMIN; PROTEIN STRUCTURE, TERTIARY; THROMBOMODULIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0141498145     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00329.x     Document Type: Review

References (70)

1. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
2. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
3. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
4. CampbellW, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
5. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
6. Mosnier LO, dem Borne PAK, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
7. Erdös EG, Sloane EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 1962; 11: 585-92.
8. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
9. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
10. Von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
11. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
12. Bouma BN, Marx PF, Mosnier LO, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
13. 2-macroglobulin and pregnancy zone protein. J Biol Chem 1996; 271: 12937-43.
14. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
15. Marx PF, Bouma BN, Meijers JCM. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 1211-6.
16. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
17. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
18. Reverter D, Vendrell J, Canals F, Horstmann J, Aviles FX, Fritz H, Sommerhoff CP. A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis - Isolation, sequence analysis, cDNA cloning, recombinant expression, and characterization. J Biol Chem 1998; 273: 32927-33.
19. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
20. Christensen U. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen. FEBS Lett 1985; 182: 43-6.
21. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-8.
22. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-90.
23. Walker JB, Boffa MB, Nesheim ME. Molecular mass dependence and the effect of TAFIa on the t-PA and DSPA cofactor activities of soluble fibrin degradation products. Fibrinol Proteol 1998; 12: 11 [Abstract].
24. Stewart RJ, Fredenburgh JC, Rischke JA, Bajzar L,Weitz JI. Thrombinactivable fibrinolysis inhibitor attenuates (DD) E-mediated stimulation of plasminogen activation by reducing the affinity of (DD) E for tissue plasminogen activator - A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J Biol Chem 2000; 275: 36612-20.
25. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
26. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-52.
27. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulindependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
28. Kokame K, Zheng XL, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 1998; 273: 12135-9.
29. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-78.
30. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
31. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 6547-58.
32. Schneider M, Boffa M, Stewart R, Rahman KoschinskyM, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
33. Barbosa Pereira PJ, Segura-Martín S, Oliva B, Ferrer-Orta C, Aviles FX, Coll M, Gomis-Ruth FX, Vendrell J. Human procarboxypeptidase B. Three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol 2002; 321: 537-47.
34. Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF. Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 2000; 292: 25-40.
35. Marx PF, Dawson PE, Bouma BN, Meijers JCM. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
36. Meijers JCM, Oudijk EJD, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108: 518-23.
37. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-8.
38. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3: 465-8.
39. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
40. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
41. Von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of Factor XI results in a thrombinactivatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
42. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
43. Mosnier LO, Lisman T, Van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-9.
44. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
45. Vlieg AV, Van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-82.
46. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
47. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
48. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
49. Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. Plasma thrombinactivatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
50. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
51. Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80: 949-55.
52. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
53. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-3.
54. Trégouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAR gene polymorphisms. Hum Genet 2001; 109: 191-7.
55. Giles A, Alessi MC, Brouwers E, Peeters M, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325 specific procpu/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; May 1: epub ahead of print.
56. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
57. Mosnier LO, Meijers JCM, Bouma BN. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis. Thromb Haemost 2001; 86: 1040-6.
58. Mosnier LO, Elisen MGLM, Bouma BN, Mejers JCM. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the upand down regulation of TAFI activation. Thromb Haemost 2001; 86: 1057-64.
59. Minnema MC, Friederich PW, von Levi M, dem Borne PA,Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
60. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity - A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
61. Hudson I, DeBono DP. Levels of carboxypeptidase B (thrombin activatable fibrinolysis inhibitor, TAFI) following thrombolysis with streptokinase. Fibrinol Proteol 1998; 12: 12 [Abstract].
62. Nagashima M,Werner M,Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
63. Refino CJ, DeGuzman L, Schmitt D et al. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis. Fibrinol Proteol 2000; 14: 305-14.
64. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
65. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
66. Wagenaar GTM, Girma M, Havik SR, Voskuilen MC, Bouma BN, Meijers JC. Generation and characterization of thrombin activatable fibrinolysis inhibitor deficient mice. Thromb Haemost 2001; 86(Suppl.): OC1759 [Abstract].
67. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
68. Biemond BJ, Havik SR, Meijers JCM. Absence of enhanced lysis of pulmonary microemboli in TAFI deficient mice. Blood 2001; 98: 255a [Abstract].
69. te Velde EA, Wagenaar GTM, Reijerkerk A, Roose-Girma M, Borel Rinkes HM, Voest EE, Bonma BN, Gebbink MFBG, Meijers JCM. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: in press.
70. Bouma BN, dem Borne PAK, Meijers JCM. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.